Eric Coldwell
Stock Analyst at Baird
(3.58)
# 820
Out of 4,749 analysts
176
Total ratings
54.37%
Success rate
4.31%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings | Maintains: Neutral | $354 → $362 | $350.04 | +3.42% | 17 | Jan 27, 2025 | |
| IQV IQVIA Holdings | Maintains: Neutral | $212 → $210 | $201.78 | +4.07% | 16 | Jan 21, 2025 | |
| FTRE Fortrea Holdings | Downgrades: Neutral | $28 → $25 | $16.75 | +49.25% | 7 | Dec 6, 2024 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $249 → $225 | $201.72 | +11.54% | 18 | Nov 20, 2024 | |
| MCK McKesson | Upgrades: Outperform | $531 → $688 | $604.60 | +13.79% | 17 | Nov 7, 2024 | |
| PINC Premier | Maintains: Neutral | $19 → $20 | $23.00 | -13.04% | 6 | Nov 6, 2024 | |
| AHCO AdaptHealth | Maintains: Outperform | $16 → $14 | $10.71 | +30.72% | 9 | Nov 6, 2024 | |
| OMI Owens & Minor | Maintains: Neutral | $19 → $14 | $14.60 | -4.11% | 14 | Nov 5, 2024 | |
| LH Labcorp Holdings | Maintains: Outperform | $282 → $289 | $251.54 | +14.89% | 12 | Oct 25, 2024 | |
| DGX Quest Diagnostics | Upgrades: Outperform | $157 → $182 | $164.17 | +10.86% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $190 | $165.57 | +14.76% | 12 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $137 | $128.26 | +6.81% | 11 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $51 | $11.46 | +345.03% | 16 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $63.51 | -29.15% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $56.82 | +16.16% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $1.67 | +2,654.66% | 4 | Nov 10, 2017 |
Medpace Holdings
Jan 27, 2025
Maintains: Neutral
Price Target: $354 → $362
Current: $350.04
Upside: +3.42%
IQVIA Holdings
Jan 21, 2025
Maintains: Neutral
Price Target: $212 → $210
Current: $201.78
Upside: +4.07%
Fortrea Holdings
Dec 6, 2024
Downgrades: Neutral
Price Target: $28 → $25
Current: $16.75
Upside: +49.25%
ICON Public Limited Company
Nov 20, 2024
Maintains: Neutral
Price Target: $249 → $225
Current: $201.72
Upside: +11.54%
McKesson
Nov 7, 2024
Upgrades: Outperform
Price Target: $531 → $688
Current: $604.60
Upside: +13.79%
Premier
Nov 6, 2024
Maintains: Neutral
Price Target: $19 → $20
Current: $23.00
Upside: -13.04%
AdaptHealth
Nov 6, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $10.71
Upside: +30.72%
Owens & Minor
Nov 5, 2024
Maintains: Neutral
Price Target: $19 → $14
Current: $14.60
Upside: -4.11%
Labcorp Holdings
Oct 25, 2024
Maintains: Outperform
Price Target: $282 → $289
Current: $251.54
Upside: +14.89%
Quest Diagnostics
Oct 23, 2024
Upgrades: Outperform
Price Target: $157 → $182
Current: $164.17
Upside: +10.86%
Sep 20, 2024
Maintains: Neutral
Price Target: $191 → $190
Current: $165.57
Upside: +14.76%
Aug 15, 2024
Maintains: Outperform
Price Target: $130 → $137
Current: $128.26
Upside: +6.81%
Apr 1, 2022
Downgrades: Neutral
Price Target: $51
Current: $11.46
Upside: +345.03%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $63.51
Upside: -29.15%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $56.82
Upside: +16.16%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $1.67
Upside: +2,654.66%